PDCD1 and cancer: Interactions of several ligand-receptor pairs between cancer cells and immune cells (CD274:PDCD1, FAM3C:PDCD1, PVR:TIGIT) are predicted to be enhanced in NRF2 signature high samples which could be potential targets to inhibit to remodel the TME.